Could Co-Diagnostics’ Saudi manufacturing move strengthen its molecular diagnostics strategy?
Saudi localization gives Co-Diagnostics a new opening. The test is whether CoMira can turn a factory lease into diagnostics traction.
Why Seek Labs’ amplification chemistry could matter beyond infectious disease testing
Molecular testing is powerful but lab-bound. Seek Labs’ patent raises a sharper question: can point-of-care diagnostics finally scale?
What Invivoscribe’s IdentiClone Dx IGH approval reveals about the new economics of IVDR-ready hematology diagnostics
Invivoscribe’s IdentiClone Dx IGH won IVDR certification in the EU. Read what this means for clonality testing, lab adoption, and diagnostic competition.
How QIAGEN’s QIAstat-Dx Rise GI panel clearance could reshape multiplex pathogen testing in clinical labs
QIAGEN wins FDA clearance for GI panels on QIAstat-Dx Rise. Discover what this means for syndromic testing platforms and molecular diagnostics adoption.
Insight Molecular Diagnostics builds regulatory case for GraftAssureDx kidney transplant test
Insight Molecular Diagnostics advances GraftAssureDx toward FDA submission. Discover what this means for transplant rejection testing and dd-cfDNA diagnostics.
What Belay Diagnostics’ Summit 2.0 results reveal about the future of CNS molecular diagnostics
Belay Diagnostics validates its Summit 2.0 CSF genomic assay, strengthening the clinical case for liquid biopsy in CNS cancers. Read the full analysis.
Merlin CP-GEP becomes first NCCN-endorsed molecular test for early-stage melanoma risk assessment
NCCN guidelines now recommend Merlin CP-GEP for early-stage melanoma risk assessment. Discover what this changes for clinicians and diagnostics adoption.
Ambient-temperature RNA-ISH enters mainstream pathology as Molecular Instruments expands HCR Pro automation
Discover how Molecular Instruments’ ambient-temperature HCR Pro RNA-ISH on BOND-III could reshape clinical pathology automation and RNA diagnostics.
New England Biolabs strengthens liquid biopsy foundations with scalable cfDNA extraction launch
New England Biolabs launches an automation-ready cfDNA extraction kit. Find out what this changes for liquid biopsy workflows and diagnostics development.
Is Zepto Life Technology redefining fungal diagnostics with cell-free DNA technology?
Zepto Life Technology’s FungiFlex Mold Panel enables fast, noninvasive fungal diagnostics from blood. Find out what this could mean for patient care.